PARTIALLY EXCLUDED POLICY – 112
BREAST REDUCTION SURGERY FOR GYNECOMASTIA
(Previously PE5b)

Policy author: Ipswich and East Suffolk Clinical Commissioning Group and West Suffolk Clinical Commissioning Group supported by Public Health Suffolk, Suffolk County Council

Policy start date: February 2017

Review date: February 2020

1. Policy Summary

1.1 Surgical management of male gynecomastia is considered a low priority procedure and will not normally be funded. Funding requests are considered by the Suffolk CCG’s Individual Funding Request (IFR) Panel if there are exceptional circumstances i.e. there is something about the patient’s condition or circumstances that differentiate them on the basis of need from other patients with a similar diagnosis or condition and would justify funding being provided in an individual case when it is not routinely funded for others.

1.2 This partially excluded policy offers some guidance to the referring clinician and the IFR Panel when considering such requests. It must be clarified these are NOT referral criteria, and only supporting guidance for the IFR panel.

2. Background to the Procedure

2.1 Gynecomastia (enlargement of the male breast tissue) is a common benign condition with up to 70% of boys developing pubertal gynecomastia and approximately 2/3 adult men having palpable breast tissue. It is separate from pseudo gynecomastia, also known as lipomastia, where breasts are larger due to increased adipose tissue. In most cases a thorough history and physical examination, along with laboratory investigations, helps to exclude breast malignancy and any serious underlying endocrine or systemic disease, as well as to identify pseudo gynecomastia. Careful clinical observation may then be all that is necessary, because gynecomastia often resolves spontaneously, especially in the case of adolescence, with regard to pubertal gynecomastia.

3. Rationale Behind Policy Decision

3.1 Surgery for gynecomastia is considered a cosmetic procedure. Cosmetic procedures are defined as “the choice to undergo an operation, or invasive medical procedure, to alter one’s physical appearance for aesthetic rather than medical reasons.” For this intention it is not routinely funded by the clinical commissioning group. It will be considered in certain exceptional cases as outlined below.

4. Guidance to Panel

4.1 Clinical Examination Findings (including BMI and reported visual irregularities)
a) True gynecomastia is benign enlargement of male breast tissue. It can be defined as the presence of >2cm palpable, firm, subareolar gland and ductal tissue (not fat).

b) Surgery to correct unilateral or bilateral gynecomastia should be considered if the patient:

- Is post pubertal (stable height for past 6 months). AND

- Has BMI < 25 kg/m² with evidence that the patient’s weight has been stable for 2 years. A BMI of 25 kg/m² represents a normal BMI outside the excess weight category and the stability of this for 2 years signifies a stable body mass thus avoiding risky surgery to those whose gynecomastia is related to excess weight. AND

- Has breast enlargement on at least one side which is Grade III or above using Cordova’s classification system (see appendix) OR has unilateral breast enlargement with a difference of at least 2 grades (e.g. normal and Grade II differential).

c) Scarring, contour irregularities and moderate asymmetry (including dog-ears, nipple direction or position, breast size and shape disparity) are predictable following surgery. Any post-surgical cosmetic irregularities will not be funded by the CCG in revision surgery.

4.2 Investigations and Conditions of Exemption

a) True gynecomastia will be considered for funding (i.e. true breast tissue is present not just adipose tissue – pseudo gynecomastia) as above. The clinician should, however, ensure that the following are confirmed:

- Breast cancer has been ruled out as suspicion of cancer exempts the patient from this guidance. It is important that male breast cancer is not mistaken for gynecomastia and, if there is any doubt, an urgent consultation with an appropriate specialist should be obtained.

- Testicular cancer has been ruled out as suspicion of cancer exempts the patient from this guidance.

- Underlying endocrine or liver abnormality has been ruled out as these are separate medical conditions that exempt a patient from this guidance and alternative treatment of these conditions is likely necessary if confirmed as surgical intervention will not resolve the causative factors.

- The condition is not due to the abuse of drugs with bodybuilding – certain medications and drugs contribute to gynecomastia in males.

- The condition is not a side effect of medication or drugs e.g. spironolactone, cimetidine, digoxin or cannabis - certain medications can contribute to the development of gynecomastia and if confirmed the individual may need to undergo further clinical evaluation for alternative treatments or medication adjustments of the treated condition as surgical intervention will not resolve the causative factors.

4.3 Minimum Age
Patient is minimum 19 years of age as puberty most often is occurring up to this age and the hormonal changes associated with this process contribute to male gynecomastia. Ensuring the individual is 19 year of age prior to consideration of surgical treatment prevents performing risky surgical treatment on a condition that may resolve when puberty is reached.

4.4 Smoking Status

a) Stipulate that patients who smoke undergoing this operation must cease smoking 3-4 weeks prior to surgery at their pre-operative consultation and urge that they continue to abstain from all forms of smoking for 3-4 weeks during the post-operative phase. Advise the patient that use of electronic nicotine delivery systems and other forms of nicotine (i.e. patch, gum) will show positive cotinine levels in their saliva and may trigger a positive test result when checked. AND

b) Encourage the patient to complete a smoking cessation course with the local commissioned smoking cessation provider prior to their operation to help their abstinence. AND

c) Stipulate that the patient undertakes a cotinine test within the 4 week window prior to their surgery to demonstrate that they are not smoking (cotinine level >10 ng/mL indicates that the patient is smoking).

d) Advise the patient that failure to comply with these criteria will lead to their surgery being cancelled.

4.5 Additional Request Submission Requirements:

Applications must include at least 2 colour photographs of the chest. Photographs should go from the top of the chest down to the umbilicus. One should be taken from directly in front of the patient and another at an angle of 45 degrees (see the attached classification photos, Grades II – IV, for examples).
4.6 **Appendix – Classification of Gynecomastia**

**CLASSIFICATION OF GYNECOMASTIA**

<table>
<thead>
<tr>
<th>Grade I</th>
<th>Grade II</th>
<th>Grade III</th>
<th>Grade IV</th>
</tr>
</thead>
</table>

Classification of gynaecomastia. Grade I, increase in diameter and protrusion limited to the areolar region; Grade II, areola-nipple complex above the inframammary fold (I.F.); Grade III, areola-nipple complex at the same height as or about 1cm below the I.F.; Grade IV, areola-nipple complex more than 1cm below the I.F.

5. **References**


